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Introduction
The past few decades have witnessed considerable advances in our understanding of the molecular basis of pathophysiology underlying a wide range of diseases, including cancer. This knowledge has provided a platform for the development of molecular therapies aiming to specifically inhibit oncoproteins involved in signal transduction within tumor cells. This therapeutic concept has currently moved beyond the proof-of-concept stage; a substantial number of such inhibitors is successfully developed and presently in use against various cancers in the clinic, some of which have produced significant outcomes (1).
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome (Ph), which is identifiable by cytogenetic analysis throughout the course of the disease (2) . The Ph results from a reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11), leading to the formation of a novel fusion gene, Bcr-abl. Since the subsequent chimeric BCR-ABL tyrosine kinase possesses constitutive activity and plays a critical role in the pathogenesis of CML (3, 4) , it is not surprising that the introduction of imatinib mesylate (IM; previously known as STI571) -the first approved tyrosine kinase inhibitor -which functions by blocking the ATP binding site of BCR-ABL (5 ), has radically innovated the treatment of chronic phase CML (6) . Patients with more advanced phases also respond to IM, but disappointingly this occurs much less frequently and efficacy is less durable (7) . Therefore, second-generation compounds, such as nilotinib (NL) and dasatinib (DS), are now available for the treatment of CML patients in whom IM treatment is ineffective (8) . Similar newer agents, which are currently in clinical trials, might also be expected to enter the market in the very near future. As a favorable outcome in first-line therapy is critical for obtaining a better prognosis in CML patients (9) , these rapid advances in treatment, in turn warrant the development of techniques for evaluating drug efficacy in each individual patient, not only at the time of initial diagnosis but also during the course of the disease, thus increasing the likelihood of therapeutic success.
FRET-based biosensor to measure BCR-ABL activity
5/29
CrkL, a member of the Crk adaptor molecules, mediates a variety of pathophysiological signaling involved in cell proliferation, differentiation, migration, and transformation (10) . Like the other family member CrkII, it consists of one src homology (SH) 2 domain, two SH3 domains, and a tyrosine residue that is phosphorylated by cellular tyrosine kinases. In human CML cells, CrkL is identified as a major substrate of BCR-ABL and is constitutively phosphorylated, playing important roles in oncogenic signal transduction (11) (12) (13) ). As such, the level of CrkL phosphorylation, as analyzed by immunoblotting, has been utilized as a marker of BCR-ABL activity and drug responses (14) . In this study, we develop an original system to determine BCR-ABL activity and its inhibition in response to drug treatment in living cells using the principle of fluorescence resonance energy transfer (FRET). The probe molecule constructed here measures BCR-ABL activity as changes in FRET efficiency, which facilitates the assessment of drug efficacy at a single cell level.
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Materials and Methods
Plasmids, reagents, and antibodies. Details about the construction of plasmids are described in Supplementary Data. Imatinib mesylate (IM) and nilotinib (NL) were kind gifts from Novartis Pharma; Dasatinib (DS) was from Bristol-Myers Squibb. Anti-CrkL antibody (#3182; 1:1000 dilution) and anti-phospho CrkL (Y207) antibody (#3181; 1:1000 and 1:500 dilutions for immunoblotting and immunofluorescence, respectively) were purchased from Cell Signaling Technology, while anti-c-Abl antibody was obtained from Santa Cruz Biotechnology (sc-23; 1:500 and 1:100 dilutions).
Cell culture and transfection. 293F cells were purchased from Invitrogen, maintained in Gene transfer into these cells was performed using nucleofection according to the manufacturer's recommendations (Amaxa Biosystems)-approximately 30% transfection efficacy was obtained for these leukemia cell lines.
Fluorescence spectrometry and immunoblotting. Cells were transfected with Pickles, with or without pCMV-3Myc-BCR-ABL. From 24 h after transfection, a fluorescence spectrum was obtained by means of a FP-6500 fluorescence spectrometer (JASCO Co.), with an excitation wavelength of 420 nm. In some experiments the cells were treated with IM (as indicated in the Figure Legends ) before spectrometric analysis. To obtain the spectra of cell lysates, cells were harvested by centrifugation, lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5% NP-40), clarified by additional centrifugation, and subjected to spectroscopy. The same lysates were analyzed by immunoblotting as described previously (15) .
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Fluorescence microscopy. Cells expressing Pickles were cultured in phenol red-free RPMI 1640 medium (Invitrogen) buffered with 15 mM HEPES pH 7.4 (to avoid CO 2 control), plated on a poly-L-lysine-coated glass base plate (Asahi Techno Glass Co.), and treated with indicated doses of IM, NL, and DS. Cell image acquisition was performed as described previously (see also Supplementary Data) (16) . Following background subtraction, FRET/ECFP ratio images were created using MetaMorph software and the images were used to illustrate FRET efficiency.
In the dot plots, the absolute values for FRET/ECFP were calculated and plotted; one dot representing the FRET efficiency of a single cell.
Flow cytometry. Cells were fixed in 4% paraformaldehyde for 30min at room temperature, permeabilized by saponin, and incubated with phospho-CrkL antibody (1:100 dilution). After extensive washing, the cells were then incubated with AlexaFluor488-conjugated secondary antibody (1:500 dilution) and subjected to flow cytometric analysis using a FACSCalibur machine (Becton, Dickinson and Company) as previously described (17) . Statistical analyses. All data, unless otherwise specified, are expressed as the mean ± standard deviation (SD), subjected to one-way analysis of variance, followed by comparison using a Student's or Welch's t-test to evaluate the difference between the drug-treated and Despite the fact that it was efficiently phosphorylated, the prototype Pickles (Pickles-1.00)
showed only a marginal difference in FRET efficiency in the presence of BCR-ABL ( Fig. 1C ; Supplementary Fig. S1A ). Since the use of a truncated form of CrkII, a Crk family member highly homologous to CrkL, was previously reported to have improved the increase in FRET efficiency of a similar CrkII FRET-based probe (19), we substituted CrkL in Pickles-1.00 with a carboxyl terminus-truncated form (corresponding to amino acids 1-222) of CrkL (Fig. 1B) . The FRET efficiency of Pickles-2.00 was significantly increased (by up to 30%) in the presence of BCR-ABL ( Fig. 1C ; Supplementary Fig. S1A ).
To expand the dynamic range of Pickles-2.00, we introduced circular permutations, one of the rational methods to refine FRET probes (20) , in ECFP (cpECFP), in which the N-and Cterminal portions were interchanged and the original termini were reconnected by a short spacer (Fig. 1B) . Among the several probes constructed, Pickles-2.30 exhibited the most significant increase in FRET efficiency (~40%) in the presence of BCR-ABL ( Fig. 1C ; Supplementary Fig.   S1A ). To further confirm that the increase in emission ratio was in fact due to the intra-molecular binding of the SH2 domain to phosphorylated Y207, we used three mutants, Pickles-R39V (SH2 domain mutant), Pickles-W160L (N-terminal SH3 domain mutant), and Pickles-Y207F (Y207 mutant). The FRET efficiency of Pickles-R39V and -Y207F failed to increase with BCR-ABL expression, whereas the increase of Pickles-W160L was comparable to that of wild-type Pickles ( Supplementary Fig. S1F ). As expected, these mutants, except for Pickles-Y207F, were efficiently phosphorylated by BCR-ABL, as measured by immunoblotting ( Supplementary Fig.   S1G ). Since R39 in the SH2 domain is a critical amino acid for phosphotyrosine recognition, presumably Y207 in this case, these experiments reveal that the binding between the SH2 domain and phosphorylated Y207 dictates FRET increase in Pickles. We also confirmed that FRET-based biosensor to measure BCR-ABL activity
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FRET was indeed the source of this increase in emission ratio through the digestion of Pickles with proteinase K (Supplementary Fig. S1H ). Taken together, these results verify that Pickles reports BCR-ABL activity by FRET in response to its SH2-phosphotyrosine binding.
Assessment of the effect of imatinib on BCR-ABL activity using Pickles. Next, we utilized
Pickles to assess the effect of IM on BCR-ABL activity in K562 cells. As expected, FRET efficiency decreased in a dose-dependent manner; the reduction becoming significant at a concentration ≥ 0.1 μM ( Fig. 2A ; Supplementary Fig. S2A ); however, when we observed the phosphorylation status of endogenous CrkL by immunoblotting and flow cytometry, at least 1 and 0.5 μM IM respectively, were required to produce a significant difference ( Figs Supplementary Movie S1). Pickles therefore, being both highly sensitive and practical to use, seems to be a valuable tool to estimate drug efficacy in CML therapy.
Evaluation of the influence of second-generation drugs on BCR-ABL mutants using
Pickles. The most serious issue in current IM therapy for CML is the emergence of IM-refractory clones due to various mechanisms; point mutations within the ABL kinase domain being known as the most frequent one (23) , stimulating the development of new kinase inhibitors such as NL and DS that are able to override resistance to IM. Pickles could be used successfully to show that the kinetics of these second-generation drugs were faster than that of IM in K562 cells (Fig. 2D , upper panel), in consistence with previous reports (24, 25) . To decipher the drug susceptibility of IM-resistant BCR-ABL mutants by Pickles, we prepared constructs for two BCR-ABL mutants, G250E and T315I (26) . As expected, these mutants are capable of persistent phosphorylation of
CrkL even in the presence of IM, as measured by immunoblotting ( Supplementary Fig. S3 ) as well as by Pickles (Fig. 3A) . We could also visualize the drug susceptibility of these mutants in (26) . Interestingly, although the inhibitory effect of NL on the kinase activity of G250E appeared to be dose-dependent (Fig. 3A) ,
we also noticed the presence of cells, in which FRET efficiency remained high even after 24 h of drug treatment. This happened mostly in the cells expressing higher levels of G250E BCR-ABL (Fig. 3C ).
Since the inhibitory effect of NL on G250E BCR-ABL remains controversial (26, 27) , the above observations encouraged us to examine whether the expression level of BCR-ABL was in any way related to drug resistance, as has already been proposed (28) . Time-lapse analysis revealed a difference in the kinetics of the decrease in FRET efficiency in cells with high and low expression levels of G250E BCR-ABL (Fig. 3B) . This difference might be attributed to residual BCR-ABL activity even after NL treatment, which is specifically observed in cells expressing high levels of BCR-ABL at doses of 2 and 20 μM (Fig. 3C ). Based on these results, we can state that the expression level of BCR-ABL, particularly that of the G250E mutant, is a determining factor for drug sensitivity. It is noteworthy that even the cells with the high G250E expression became NL-sensitive by pretreatment with IM ( Supplementary Fig. S3C ), which might be accounted for by the synergistic effect between IM and NL as reported (8) . These findings further emphasize the indispensable role for this system in determining the most effective drug or drug combinations for BCR-ABL mutants, whichever these may be. Fig. S4B ; see also "Materials and Methods"), into the analyses.
We Fig. S4B ).
In contrast, more than 50% FRET hi cells can be detected within a native BCR-ABL-expressing cell population, which disappears by drug treatment ( Supplementary Figs. S4C and D).
To mimic a more realistic scenario, namely that just a small number of drug-resistant cells Supplementary Fig. S5A ). In terms of minor drug-resistant cell population detectability, we imagined that a flow cytometric method, which allows for higher throughput analysis might offer advantages over our method, in which the analyzed cell number was limited up to 500 due to manual observation using microscopy. Unexpectedly however, these two methods yielded comparable results, with ~1% of IM-resistant cells within samples being detected ( Figs. S6B and C). Due to the low FRET efficiency exhibited by almost all CML cells, we could obtain significant differences between healthy volunteer and CML patient cells only by using the mean FRET efficiency of the top quartile, but not that of the entire cell population (Fig. 5A, The results above indicated that case #3 possessed IM-refractory tumor cells in the BM but not in the PB, which encouraged us to carry out a careful follow-up of all three patients during IM treatment. As we anticipated, case #3 achieved complete hematologic response within 2 months, but no CCyR even after 12 months (suboptimal response). Case #1 displayed CCyR after IM administration (optimal response), while case #2 could not be successfully managed with IM therapy, and underwent bone marrow transplantation following detection of the multidrug resistant mutation T315I in the Bcr-abl gene. In view of the results we are obtaining, we feel confident that following our study using a large patient cohort, this Pickles-based method will be used successfully to provide reliable information regarding drug sensitivity in CML, both at the time of initial diagnosis and during the course of the disease, as well as to predict potential future recrudescence during/after IM therapy.
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Discussion
In the present study, we have developed a FRET-based biosensor, Pickles, which enables the evaluation of BCR-ABL kinase activity in living cells in a quick and efficient manner. To our knowledge, this is the first report in which GFP-based FRET technology is applied to such a clinical scene: evaluation of molecular targeted drug efficacy. The discriminatory nature of our method should also be emphasized. Pickles reports the dynamic, functional activity of 'live' BCR-ABL protein, which is essentially different from other conventional methods, wherein the information obtained is limited to the amount of BCR-ABL or the static states of CrkL phosphorylation levels after fixation.
The existence of the Ph is the reigning hallmark of disease progression in CML, and its reduction during/after therapy is strikingly associated with the prognoses of CML patients (32) . with regard to analysis of individual cells (41, 42) , another concern associated with these methods remains: selective rapid degradation of BCR-ABL after lysis or permeabilization (43) .
Therefore, the results obtained by means of the abovementioned techniques will always suffer from the possible underestimation of BCR-ABL activity, which can result in lower sensitivity than expected. In fact, the FRET-based technique described in this study, showed similar detectability of small drug-resistant cell populations to that of flow cytometry in spite of its high throughput property (Fig. 4) . Given that Pickles can visualize the dynamics of BCR-ABL activity in response to drugs, it apparently exceeds other methods regarding overall detectability.
The abovementioned high performance of Pickles enables the observation of BCR-ABL activity at a single cell level even if the expression levels or mutant status are variable among cells (Fig. 3) . Clinical resistance to IM is attributed to amplification of the Bcr-abl gene, clonal Our method disclosed the underlying cause of these paradoxical findings by observation of BCR-ABL activity at a single cell level (Fig. 3) ; the sensitivity of BCR-ABL harboring the G250E mutation to NL was totally dependent on its expression level (Fig. 3 ). This observation apparently provides a guideline for more accurate decision-making regarding NL treatment in the treatment of patients with the G250E mutation.
From another point of view, our method is of significance with regard to the recent emergence of allosteric inhibitors of BCR-ABL. The combined application of this reagent with authentic ATP competitive inhibitors leads to complete disease remissions in an in vivo murine CML model (45) . Because these new drugs bind to a site far from activation loops, the mutations that affect their sensitivity will be completely different from the ones identified for the authentic drugs, suggesting that, to determine the drug efficacy only by sequencing analysis, we must perform an exhaustive search for almost all regions in the Bcr-abl gene. Our method will definitely be of great help in such a situation by reporting the direct efficacy of any drugs to any types of BCR-ABL without DNA/RNA sequencing. The technique described in this study can detect minor drug-resistant populations within heterogeneous cell populations, making it ideal for the evaluation of drug efficacy in CML patients prior to the initiation of CML therapy, which is of great benefit to both patients and physicians. In fact, our results suggest that the evaluation of BCR-ABL kinase inhibition using
Pickles might also be a predictor of long-term molecular responses (Fig. 5) , thus allowing for the selection of the best therapeutic approach more accurately than current methods. The Picklesbased method may also be useful in identifying the most suitable treatment for IM-resistant cells irrespective of the refractory mechanism in future; it can be applied to evaluate the effect of newer drugs on CML stem cells and can also be easily incorporated in a high-throughput screening system for the discovery of other tyrosine kinase inhibitors. Hence, following further clinical study, the addition of this novel prognostic molecular response indicator to the present CML therapeutic armamentarium is ultimately envisaged. 
